Venetoclax Combo Multiple Myeloma Treatment Results
Okay, here’s a breakdown of the provided text, focusing on key findings and study details. I’ll organize it into sections for clarity.
1.Study Overview (BELLINI Study)
* Purpose: To evaluate the efficacy and safety of venetoclax in combination with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.
* Design: Randomized, 2:1 ratio (venetoclax vs. placebo).
* Participants: 291 patients with relapsed/refractory multiple myeloma, 1-3 prior lines of therapy, and good performance status (ECOG 0-2).
* Treatment:
* Venetoclax Group (n=194): 800 mg daily venetoclax + bortezomib (1.3 mg/m2) + dexamethasone (20 mg)
* Placebo Group (n=97): Placebo + bortezomib (1.3 mg/m2) + dexamethasone (20 mg)
* Cycles: Initial 8 cycles were 21 days long, followed by ongoing treatment in 35-day cycles with adjusted bortezomib dosing.
2. Key Efficacy Results
* Overall Response Rate (ORR): Significantly higher in the venetoclax group (84%) compared to placebo (70%) (P = .0088).
* Duration of Response: Much longer in the venetoclax group (26.7 months) vs. placebo (12.8 months) (HR 0.514; P = .00012).
* Minimal Residual Disease (MRD) Negativity: Higher rate in the venetoclax group (15%) vs. placebo (2%) (P = .0012).
* Time to Progression: Significantly longer in the venetoclax group (24.7 months) vs. placebo (11.4 months) (HR 0.530; P < .0001).
* Disease Symptom Deterioration: Less deterioration in the venetoclax group (48%) compared to placebo (58%) (HR 0.65; P = .013). The time to deterioration was also longer with venetoclax (12.5 months) vs. placebo (4.3 months).
3. Biomarker Findings
* The study suggests potential benefits of venetoclax in patients with relapsed/refractory multiple myeloma who have a t(11;14) translocation and/or high BCL2 expression. This supports a biomarker-driven approach to treatment.
4. Safety
* The most common treatment-emergent adverse events were diarrhea, thrombocytopenia, and nausea in both groups.
* The safety profile was described as “manageable” with venetoclax.
In essence, the BELLINI study demonstrates that adding venetoclax to standard bortezomib and dexamethasone therapy significantly improves outcomes (response rate, duration of response, progression-free survival, symptom control) in patients with relapsed/refractory multiple myeloma, particularly those with specific genetic/molecular features.